vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and LCNB CORP (LCNB). Click either name above to swap in a different company.
LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $20.0M, roughly 1.2× AGIOS PHARMACEUTICALS, INC.). LCNB CORP runs the higher net margin — 23.7% vs -541.1%, a 564.8% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs 5.1%). LCNB CORP produced more free cash flow last quarter ($33.4M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 15.7%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
AGIO vs LCNB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $23.9M |
| Net Profit | $-108.0M | $5.7M |
| Gross Margin | 90.6% | — |
| Operating Margin | -608.9% | 29.2% |
| Net Margin | -541.1% | 23.7% |
| Revenue YoY | 86.1% | 5.1% |
| Net Profit YoY | -11.9% | -7.6% |
| EPS (diluted) | $-1.86 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $23.9M | ||
| Q3 25 | $12.9M | $23.8M | ||
| Q2 25 | $12.5M | $22.8M | ||
| Q1 25 | $8.7M | $21.5M | ||
| Q4 24 | $10.7M | $22.7M | ||
| Q3 24 | $9.0M | $21.4M | ||
| Q2 24 | $8.6M | $19.3M | ||
| Q1 24 | $8.2M | $17.8M |
| Q4 25 | $-108.0M | $5.7M | ||
| Q3 25 | $-103.4M | $6.9M | ||
| Q2 25 | $-112.0M | $5.9M | ||
| Q1 25 | $-89.3M | $4.6M | ||
| Q4 24 | $-96.5M | $6.1M | ||
| Q3 24 | $947.9M | $4.5M | ||
| Q2 24 | $-96.1M | $925.0K | ||
| Q1 24 | $-81.5M | $1.9M |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 92.3% | — |
| Q4 25 | -608.9% | 29.2% | ||
| Q3 25 | -907.4% | 35.6% | ||
| Q2 25 | -1020.1% | 31.6% | ||
| Q1 25 | -1222.0% | 25.6% | ||
| Q4 24 | -1165.3% | 32.9% | ||
| Q3 24 | -1146.9% | 24.9% | ||
| Q2 24 | -1228.3% | 4.9% | ||
| Q1 24 | -1124.3% | 12.5% |
| Q4 25 | -541.1% | 23.7% | ||
| Q3 25 | -803.1% | 29.1% | ||
| Q2 25 | -899.4% | 26.0% | ||
| Q1 25 | -1023.3% | 21.4% | ||
| Q4 24 | -899.6% | 27.0% | ||
| Q3 24 | 10574.7% | 21.2% | ||
| Q2 24 | -1115.7% | 4.8% | ||
| Q1 24 | -995.8% | 10.7% |
| Q4 25 | $-1.86 | $0.40 | ||
| Q3 25 | $-1.78 | $0.49 | ||
| Q2 25 | $-1.93 | $0.41 | ||
| Q1 25 | $-1.55 | $0.33 | ||
| Q4 24 | $-1.44 | $0.44 | ||
| Q3 24 | $16.22 | $0.31 | ||
| Q2 24 | $-1.69 | $0.07 | ||
| Q1 24 | $-1.45 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $21.6M |
| Total DebtLower is stronger | — | $104.4M |
| Stockholders' EquityBook value | $1.2B | $273.9M |
| Total Assets | $1.3B | $2.2B |
| Debt / EquityLower = less leverage | — | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | $21.6M | ||
| Q3 25 | $92.7M | $35.9M | ||
| Q2 25 | $80.9M | $49.8M | ||
| Q1 25 | $79.0M | $37.7M | ||
| Q4 24 | $76.2M | $35.7M | ||
| Q3 24 | $253.7M | $39.4M | ||
| Q2 24 | $84.5M | $34.9M | ||
| Q1 24 | $118.8M | $33.0M |
| Q4 25 | — | $104.4M | ||
| Q3 25 | — | $104.7M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $104.6M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $155.7M | ||
| Q2 24 | — | $162.2M | ||
| Q1 24 | — | $162.6M |
| Q4 25 | $1.2B | $273.9M | ||
| Q3 25 | $1.3B | $269.9M | ||
| Q2 25 | $1.4B | $263.5M | ||
| Q1 25 | $1.5B | $258.7M | ||
| Q4 24 | $1.5B | $253.0M | ||
| Q3 24 | $1.6B | $253.2M | ||
| Q2 24 | $660.5M | $245.2M | ||
| Q1 24 | $743.9M | $233.7M |
| Q4 25 | $1.3B | $2.2B | ||
| Q3 25 | $1.4B | $2.2B | ||
| Q2 25 | $1.5B | $2.3B | ||
| Q1 25 | $1.6B | $2.3B | ||
| Q4 24 | $1.7B | $2.3B | ||
| Q3 24 | $1.8B | $2.3B | ||
| Q2 24 | $773.1M | $2.4B | ||
| Q1 24 | $849.7M | $2.3B |
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.66× | ||
| Q1 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $34.4M |
| Free Cash FlowOCF − Capex | $-97.3M | $33.4M |
| FCF MarginFCF / Revenue | -487.5% | 140.2% |
| Capex IntensityCapex / Revenue | 5.6% | 4.0% |
| Cash ConversionOCF / Net Profit | — | 6.08× |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $54.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $34.4M | ||
| Q3 25 | $-88.2M | $14.0M | ||
| Q2 25 | $-77.1M | $5.5M | ||
| Q1 25 | $-111.5M | $2.2M | ||
| Q4 24 | $-133.2M | $93.2M | ||
| Q3 24 | $-84.2M | $11.9M | ||
| Q2 24 | $-72.6M | $54.9M | ||
| Q1 24 | $-99.9M | $-11.9M |
| Q4 25 | $-97.3M | $33.4M | ||
| Q3 25 | $-89.7M | $13.7M | ||
| Q2 25 | $-78.0M | $5.2M | ||
| Q1 25 | $-112.3M | $2.1M | ||
| Q4 24 | $-134.1M | $89.4M | ||
| Q3 24 | $-84.6M | $10.5M | ||
| Q2 24 | $-72.7M | $53.8M | ||
| Q1 24 | $-100.0M | $-12.8M |
| Q4 25 | -487.5% | 140.2% | ||
| Q3 25 | -696.5% | 57.4% | ||
| Q2 25 | -626.2% | 23.0% | ||
| Q1 25 | -1286.4% | 10.0% | ||
| Q4 24 | -1250.1% | 394.0% | ||
| Q3 24 | -944.2% | 49.0% | ||
| Q2 24 | -844.4% | 278.6% | ||
| Q1 24 | -1221.2% | -71.8% |
| Q4 25 | 5.6% | 4.0% | ||
| Q3 25 | 12.1% | 1.3% | ||
| Q2 25 | 7.0% | 1.0% | ||
| Q1 25 | 8.8% | 0.3% | ||
| Q4 24 | 9.0% | 16.7% | ||
| Q3 24 | 4.7% | 6.7% | ||
| Q2 24 | 1.8% | 5.9% | ||
| Q1 24 | 1.7% | 4.8% |
| Q4 25 | — | 6.08× | ||
| Q3 25 | — | 2.02× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 15.23× | ||
| Q3 24 | -0.09× | 2.63× | ||
| Q2 24 | — | 59.35× | ||
| Q1 24 | — | -6.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
